The Corina Intrauterine Drug-Eluting System, developed by Yipurun (Shanghai) Biotechnology, has been approved in China for moderate-to-severe intrauterine adhesions (IUA).
Corina System is an advanced drug-device combination therapy composed of non-degradable, medical-grade materials and infused with the active ingredient oestradiol.
As a first-in-class therapy, Corina aims to enhance female reproductive health by reducing the risk of intrauterine re-adhesion after TCRA and supporting improved endometrial growth.
The system is now cleared for use on Chinese IUA patients undergoing transcervical resection of adhesions (TCRA).
Specifically designed to fit the contours of the female uterus, Corina serves as a physical barrier upon insertion, facilitating targeted oestradiol delivery to the endometrium.
It can provide a steady release of oestradiol for up to 60 days following the procedure using Yipurun’s proprietary controlled-release technology. This supports enhanced endometrial growth.
The approval follows a randomised controlled clinical trial that showed Corina’s effectiveness compared to standard treatments.
The registration study results revealed a statistically significant and clinically meaningful reduction in intrauterine adhesion at 60 days post-procedure.
Additionally, Corina System demonstrated an improvement in endometrial thickness from baseline at 60 days post-procedure, surpassing the results achieved with standard-of-care therapy.
Based in Zhangjiang Hi-Tech Park, Shanghai, Yipurun (Shanghai) Biotechnology is a wholly owned subsidiary of Puyi (Shanghai) Biotechnology.
With expertise in biomedical material science and proprietary drug-eluting technology, Puyi Biotech and Yipurun have developed an advanced R&D pipeline focused on implantable therapeutics.
Puyi Biotech, established in 2012, has been delivering solutions for unmet clinical needs in women’s health, ENT (ear, nose, and throat), and medical aesthetics.
